🇺🇸 FDA
Patent

US 8304511

Maleamic acid polymer derivatives and their bioconjugates

granted A61KA61K47/60A61P

Quick answer

US patent 8304511 (Maleamic acid polymer derivatives and their bioconjugates) held by Nektar Therapeutics expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Nektar Therapeutics
Grant date
Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K47/60, A61P, A61P11/00, A61P25/00